CVRx, Inc. (CVRX)
NASDAQ: CVRX · IEX Real-Time Price · USD
16.38
-0.25 (-1.50%)
Apr 16, 2024, 4:00 PM EDT - Market closed

Company Description

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases.

The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally.

The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx, Inc.
CVRx, Inc. logo
Country United States
Founded 2000
IPO Date Jun 30, 2021
Industry Medical Devices
Sector Healthcare
Employees 200
CEO Kevin Hykes

Contact Details

Address:
9201 West Broadway Avenue, Suite 650
Minneapolis, Minnesota 55445
United States
Phone (763) 416-2850
Website cvrx.com

Stock Details

Ticker Symbol CVRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001235912
CUSIP Number 126638105
ISIN Number US1266381052
SIC Code 3841

Key Executives

Name Position
Kevin Hykes President, Chief Executive Officer and Director
Jared Oasheim Chief Financial Officer
Paul Verrastro Chief Marketing and Strategy Officer
Paul Pignato Vice President of Operations
Jonelle R. Burnham Vice President and General Counsel
Craig Palmer Senior Vice President of US Sales

Latest SEC Filings

Date Type Title
Apr 11, 2024 PRE 14A Other preliminary proxy statements
Feb 20, 2024 144 Filing
Feb 9, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 9, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 9, 2024 10-K Annual Report
Feb 6, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 31, 2024 8-K Current Report
Jan 25, 2024 8-K Current Report
Jan 19, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership